期刊
PHARMACEUTICS
卷 13, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics13020200
关键词
CTCL; topical formulation; bexarotene; targeted therapy; interferon; HDAC inhibitors
资金
- Japan Agency for Medical Research and Development [18lm0203062h0001]
This review evaluates the available therapeutic options for early- and advanced-stage CTCL in clinical practice, as well as the ongoing clinical trials for novel regimens in the treatment of CTCL.
Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据